Provaidya LLC, is a biopharmaceutical startup company focused on developing innovative therapies for neurodegenerative diseases. It was founded in 2013 to promote translation of rationally designed novel agents developed as therapeutics for Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases in academic settings. It has won the STTR Award for "Development of peptide inhibitors for neuroinflammation and neurodegeneration.
Our Mission
Our goal at Provaidya is to cure the spectrum of neurodegenerative diseases. In this process, Provaidya has taken first steps with evaluating novel mechanism based peptide inhibitors in models of Alzheimer's disease and Multiple Sclerosis.
“An estimated 5.4 million Americans of all ages have Alzheimer’s disease in 2016. The number is predicted to increase rapidly to an estimated 13.8 billion barring efficient drug discovery and development to prevent and cure the disease. ”